News & Updates
Abramson Cancer Center’s Dr. Carl June elected to National Academy of Sciences
Wednesday, May 13, 2020
In April the newest class of U.S. National Academy of Sciences members was announced, and included Carl June, director of the Center for Cellular Immunotherapy in the Abramson Cancer Center at the Perelman School of Medicine. Dr. June joined 120 members and 26 international members elected by his peers to NAS, recognized for “distinguished and continuing achievements in original research.” To date, there are 2,403 U.S. members of NAS and 501 international members. Dr. Carl June was honored at Philly Fights Cancer: Round 4 as one of the year’s honorees alongside Sean Parker for his work with CAR-T therapy and its subsequent historic FDA approval.
In addition to running the Center for Cellular Immunotherapy at the Abramson Cancer Center, Dr. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine and director of the Parker Institute for Cancer Immunotherapy at Penn. He is a pioneer in developing CAR T therapy, which became the nation’s first FDA-approved personalized cellular therapy for cancer in August 2017, and was approved for additional indications in 2018. Clinical trials of CAR T therapy began at Penn in 2010, and two of the first three patients to receive the therapy, for chronic lymphocytic leukemia, remain in remission. June also led the first U.S. trial involving CRISPR gene-edited immune cells to treat human cancer patients.
Dr. June has published more than 450 manuscripts and has received numerous prizes and honors, including being named to Time magazine’s list of the 100 most influential people in the world and by election to the Institute of Medicine. He has been honored with the Paul Ehrlich and Ludwig Darmstaedter Prize, William B. Coley Award, Karl Landsteiner Memorial Award, Richard V. Smalley Memorial Award from the Society for Immunotherapy of Cancer, Philadelphia Award, the Hamdan Award for Medical Research Excellence, Novartis Immunology Award for Cancer Cell Therapy Development, and Albany Prize.
To learn more about Dr. Carl June’s accomplishments, and read the full story from Penn Today, see here: https://penntoday.upenn.edu/news/kathleen-hall-jamieson-carl-june-elected-national-academy-sciences
Share this post
In April the newest class of U.S. National Academy of Sciences members was announced, and included Carl June, director of the Center for Cellular Immunotherapy in the Abramson Cancer Center at the Perelman School of Medicine. Dr. June joined 120 members and 26 international members elected by his peers to NAS, recognized for “distinguished and continuing achievements in original research.” To date, there are 2,403 U.S. members of NAS and 501 international members. Dr. Carl June was honored at Philly Fights Cancer: Round 4 as one of the year’s honorees alongside Sean Parker for his work with CAR-T therapy and its subsequent historic FDA approval.
In addition to running the Center for Cellular Immunotherapy at the Abramson Cancer Center, Dr. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine and director of the Parker Institute for Cancer Immunotherapy at Penn. He is a pioneer in developing CAR T therapy, which became the nation’s first FDA-approved personalized cellular therapy for cancer in August 2017, and was approved for additional indications in 2018. Clinical trials of CAR T therapy began at Penn in 2010, and two of the first three patients to receive the therapy, for chronic lymphocytic leukemia, remain in remission. June also led the first U.S. trial involving CRISPR gene-edited immune cells to treat human cancer patients.
Dr. June has published more than 450 manuscripts and has received numerous prizes and honors, including being named to Time magazine’s list of the 100 most influential people in the world and by election to the Institute of Medicine. He has been honored with the Paul Ehrlich and Ludwig Darmstaedter Prize, William B. Coley Award, Karl Landsteiner Memorial Award, Richard V. Smalley Memorial Award from the Society for Immunotherapy of Cancer, Philadelphia Award, the Hamdan Award for Medical Research Excellence, Novartis Immunology Award for Cancer Cell Therapy Development, and Albany Prize.
To learn more about Dr. Carl June’s accomplishments, and read the full story from Penn Today, see here: https://penntoday.upenn.edu/news/kathleen-hall-jamieson-carl-june-elected-national-academy-sciences